2Mehra A, JL Wrana. TGF-beta and the Smad signal transduction pathway[J]. Biochem Cell Biol, 2002, 80(5): 605-622.
3Souchelnytskyi SA, Moustakas, Heldin CH. TGF-beta signaling from a three-dimensional perspective: insight into selection of partners[J]. Trends Cell Biol, 2002, 12(7): 304-307.
4Schnaper HW, Hayashida T, Hubchak SC, et al. TGF-beta signal transduction and mesangial cell fibrogenesis[J]. Am J Physiol Renal Physiol, 2003, 284(2): F243-F252.
5Imamura T, Takase M, Nishihara A, et al. Smad 6 inhibits signalling by the TGF-beta superfamily[J]. Nature, 1997, 389(6651): 622-626.
6Uchida K, Nitta K, Kobayashi H, et al. Localization of Smad 6 and Smad 7 in the rat kidney and their regulated expression in the anti-Thy-1 nephritis[J]. Mol Cell Biol Res Commun, 2000, 4(2): 98-105.
7Monahan PE, Jooss K, Sands MS. Safety of adeno-associated virus gene therapy vectors: a current evaluation[J]. Expert Opin Drug Saf, 2002, 1(1): 79-91.
8Lai CM, Lai YK, Rakoczy PE. Adenovirus and adeno-associated virus vectors[J]. DNA Cell Biol, 2002, 21(12): 895-913.
9Nakao A, Afrakhte M. Identification of Smad 7, a TGFβ-inducible antagonist of TGF-β signaling[J]. Nature, 1997, 389: 631-635.
10Border WA, Nobel NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature, 1992,360:361-364.
8Wada T, Yokoyama H. Molecular biology in regulation of kidney functions: MCP-1/CCR2. Nippon Rinsho, 2006,64 Suppl 2:288-292.
9Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int, 2006,69:213-217.
10Macunluoglu B, Arikan H, Atakan A, et al. Effects of spironolactone in an experimental model of chronic cyclosporine nephrotoxicity. Transplant Proc, 2008,40:273- 278.
